← Back to Search

Metoprolol for Coronary Artery Disease (POINT-NOCAD Trial)

N/A

Recruiting

Led By Nathaniel Smilowitz, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Stable ischemic heart disease OR acute myocardial infarction as the indication for coronary angiography

Adult age ≥18 years referred for clinically indicated coronary angiography

Timeline

Screening 3 weeks

Treatment Varies

Follow Up visit 1, day 0

Awards & highlights

POINT-NOCAD Trial Summary

This trial is testing if a anti-inflammatory drug can help patients with ischemic heart disease who have non-obstructive coronary artery disease.

Who is the study for?

This trial is for adults over 18 with stable ischemic heart disease or acute myocardial infarction needing coronary angiography. It's not for those with poor kidney function, allergies to iodine contrast media, pregnant individuals, or anyone with significant blockage in their heart arteries.Check my eligibility

What is being tested?

The study tests if Metoprolol (a beta-blocker), Isovue and Nitroglycerin (both related to imaging procedures), along with CCTA scans can help understand inflammation in patients who have chest pain but no major artery blockages.See study design

What are the potential side effects?

Metoprolol may cause tiredness, dizziness, and cold hands/feet. Isovue might lead to allergic reactions or warmth during the scan. Nitroglycerin can cause headaches and low blood pressure. CCTA involves radiation exposure.

POINT-NOCAD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have stable heart disease or had a recent heart attack.

Select...

I am 18 or older and have been referred for a heart artery check.

POINT-NOCAD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ visit 1, day 0

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~visit 1, day 0

This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 1, day 0 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Perivascular coronary fat attenuation in patients with MINOCA will be greatest in the culprit coronary vessels with evidence of acute plaque disruption.

Perivascular coronary fat attenuation will be greater in INOCA patients with versus without coronary microvascular disease

Perivascular coronary fat attenuation will be significantly greater in MINOCA patients compared with INOCA patients

POINT-NOCAD Trial Design

1Treatment groups

Experimental Treatment

Group I: Intervention groupExperimental Treatment4 Interventions

Participants will be identified by review of the cardiac catheterization laboratory schedule each day by the principal investigator, a co-investigator, or a research coordinator. Participants with no obstructive CAD and completed microvascular testing will undergo a research CCTA.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Isovue

2014

Completed Phase 4

~150

Nitroglycerin

2006

Completed Phase 4

~2210

Metoprolol

2006

Completed Phase 4

~3730

Coronary computed tomography angiography (CCTA)

2022

N/A

~140

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor

1,367 Previous Clinical Trials

839,661 Total Patients Enrolled

Nathaniel Smilowitz, MDPrincipal InvestigatorNYU Langone Health

1 Previous Clinical Trials

165 Total Patients Enrolled

Media Library

Coronary computed tomography angiography (CCTA) Clinical Trial Eligibility Overview. Trial Name: NCT05031520 — N/A

Coronary Atherosclerosis Research Study Groups: Intervention group

Coronary Atherosclerosis Clinical Trial 2023: Coronary computed tomography angiography (CCTA) Highlights & Side Effects. Trial Name: NCT05031520 — N/A

Coronary computed tomography angiography (CCTA) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05031520 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can potential participants still join this clinical experiment?

"Clinicaltrials.gov reports that this medical study is presently searching for participants. It was initially advertised on the 12th of July 2021 and recently revised on the 1st of July 2022."

Answered by AI

May I be considered as a candidate for this research study?

"Patients with coronary artery disease that are between 18 and 125 years old can potentially enroll in this trial. A total of 100 participants is the goal for recruitment."

Answered by AI

Are there any historical instances of Coronary computed tomography angiography (CCTA) being tested in clinical trials?

"Currently, the search for a Coronary computed tomography angiography (CCTA) solution is in full swing with 28 trials under way and 4 of them at Phase 3. The majority are being conducted out of Orlando, Florida but there exists an aggregate total of 164 locations running these clinical investigations."

Answered by AI

How is Coronary computed tomography angiography (CCTA) typically employed to assist patients?

"Coronary computed tomography angiography (CCTA) is typically used to address episodes of chest pain, but can also be deployed in the treatment of myocardial infarction and adrenergic alpha-antagonist related issues. Additionally, CCTA is commonly prescribed for use as a diagnostic tool during a procedure known as myelography."

Answered by AI

How extensive is the participant base of this experiment?

"Yes, according to the current information on clinicaltrials.gov, this clinical trial is actively seeking participants and is accepting a total of 100 patients from 1 site between July 2021 and July 2022."

Answered by AI

Are participants over the age of 70 precluded from participating in this trial?

"The parameters for participation in this trial necessitate that applicants must be aged between 18 and 125. There are 53 studies open to minors, with 916 trials available for those above the age of retirement."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease

2021. "PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05031520.

All > Atherosclerosis